Tariquidar
Chemical compound
- none
- N-[2-[[4-[2-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]carbamoyl]-4,5-dimethoxyphenyl]quinoline-3-carboxamide
- 206873-63-4 Y
- 148201
- 130650 N
- J58862DTVD
- ChEMBL348475 N
- DTXSID10174746
- Interactive image
- COC1=C(C=C2CN(CCC2=C1)CCC3=CC=C(C=C3)NC(=O)C4=CC(=C(C=C4NC(=O)C5=CC6=CC=CC=C6N=C5)OC)OC)OC
InChI
- InChI=1S/C38H38N4O6/c1-45-33-18-25-14-16-42(23-28(25)19-34(33)46-2)15-13-24-9-11-29(12-10-24)40-38(44)30-20-35(47-3)36(48-4)21-32(30)41-37(43)27-17-26-7-5-6-8-31(26)39-22-27/h5-12,17-22H,13-16,23H2,1-4H3,(H,40,44)(H,41,43) N
- Key:LGGHDPFKSSRQNS-UHFFFAOYSA-N N
Tariquidar (INN/USAN) is a P-glycoprotein inhibitor[1] undergoing research as an adjuvant against multidrug resistance in cancer.
References
- ^ Robey RW, Shukla S, Finley EM, Oldham RK, Barnett D, Ambudkar SV, Fojo T, Bates SE (March 2008). "Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R))". Biochemical Pharmacology. 75 (6): 1302–12. doi:10.1016/j.bcp.2007.12.001. PMC 2346578. PMID 18234154.
- v
- t
- e